Integra Lifesciences Holdings (IART) Amortization of Deferred Charges (2009 - 2022)

Integra Lifesciences Holdings has reported Amortization of Deferred Charges for 14 years, with the latest figure at $1.6 million in Q3 2022.

• Quarterly Amortization of Deferred Charges rose 188.44% year-over-year to $1.6 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $3.6 million (up 2.85% YoY) and the FY2019 annual result came in at $5.4 million, down 14.04% from the prior year.
• Amortization of Deferred Charges improved to $1.6 million in Q3 2022 per IART's latest filing, from $1.4 million in the prior quarter.
• Over five years, Amortization of Deferred Charges peaked at $2.1 million in Q2 2018 and troughed at -$17000.0 in Q1 2022.
• A 5-year average of $1.2 million and a median of $1.4 million in 2019 frame the typical range for Amortization of Deferred Charges.
• The sharpest annual moves came in 2021 and 2022: Amortization of Deferred Charges soared 755.06% in 2021, then slumped 101.12% in 2022.
• Over 5 years, Amortization of Deferred Charges stood at $1.3 million in 2018, then soared by 45.56% to $1.9 million in 2019, then sank by 78.51% to $412000.0 in 2020, then soared by 38.59% to $571000.0 in 2021, then surged by 188.44% to $1.6 million in 2022.
• According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $1.6 million, $1.4 million, and -$17000.0 for Q3 2022, Q2 2022, and Q1 2022 respectively.